NEU Share Price

Open 0.06 Change Price %
High 0.07 1 Day 0.01 16.67
Low 0.06 1 Week 0.01 16.67
Close 0.07 1 Month 0.01 16.67
Volume 955127 1 Year 0.02 40.00
52 Week High 0.09
52 Week Low 0.04
NEU Important Levels
Resistance 2 0.08
Resistance 1 0.08
Pivot 0.07
Support 1 0.06
Support 2 0.06
ASX Australia Most Active Stocks
TLS 3.87 -10.62%
TLS 3.87 -10.62%
TLS 3.87 -10.62%
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
LYC 0.14 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
AZS 0.02 100.00%
AZS 0.02 100.00%
AZZ 0.50 78.57%
AZZ 0.50 78.57%
BNV 0.03 50.00%
PMQ 0.03 50.00%
QRX 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
AIR 0.02 -33.33%
AIR 0.02 -33.33%
AIR 0.02 -33.33%
AIR 0.02 -33.33%
More..

Neuren Pharmaceuticals Ltd (ASX: NEU)

NEU Technical Analysis 3
As on 17th Aug 2017 NEU Share Price closed @ 0.07 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.06 & Buy for SHORT-TERM with Stoploss of 0.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
NEU Target for August
1st Target up-side 0.07
2nd Target up-side 0.07
3rd Target up-side 0.07
1st Target down-side 0.05
2nd Target down-side 0.05
3rd Target down-side 0.05
NEU Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neurenpharma.com
NEU Address
NEU
697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
Phone: 61 3 9092 0480
NEU Latest News
Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials   Proactive Investors Australia   - 29th Jun 17
BRIEF-Neuren Pharmaceuticals ‍announces grant of two new patents for ...   Reuters   - 31st May 17
Neuren Pharmaceuticals drug shows promise in treating Rett syndrome   Proactive Investors Australia   - 22nd Mar 17
Neuren Pharmaceuticals granted ASX trading halt pending trial update   Proactive Investors Australia   - 20th Mar 17
Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome   Proactive Investors Australia   - 25th Aug 16
Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome   Proactive Investors Australia   - 27th Jun 16
Why the Neuren Pharmaceuticals Ltd share price has crashed today   Motley Fool Australia   - 26th Apr 16
Neuren Pharmaceuticals makes Rett Syndrome trial breakthrough   Proactive Investors Australia   - 12th Nov 14
0.065   MarketWatch   - 16th Aug 13
Neuren Pharmaceuticals' 53% share price jump prompts ASX query   Proactive Investors Australia   - 25th Oct 12
Interactive Technical Analysis Chart Neuren Pharmaceuticals Ltd ( NEU ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neuren Pharmaceuticals Ltd
NEU Business Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders primarily in the United States. Its product development pipeline includes NNZ-2566 that is in Phase II clinical trials in rett syndrome, fragile X syndrome, and moderate to severe traumatic brain injury, as well as in concussion; and NNZ-2591, which is in preclinical development for chronic neurodegenerative conditions. The company has collaborative relationship with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.